ELISA kit testing service

ELISA Kit Testing Service – Accredited Performance Validation, Batch Release and Stability Evaluation for Global Markets

Our internationally accredited laboratory delivers a comprehensive ELISA kit testing service that provides diagnostic manufacturers, pharmaceutical developers, food‑safety laboratories, environmental monitoring agencies and contract research organisations worldwide with the independent, traceable data they need to verify the sensitivity, specificity, precision, accuracy and robustness of their enzyme‑linked immunosorbent assay products. Every test is performed under the rigorous framework of ISO/IEC 17025, and each report bearing the ILAC mark is unconditionally accepted by regulatory authorities, notified bodies and supply‑chain partners in all major economies. The ELISA kit testing service covers the complete lifecycle of an immunoassay, from the development and the optimisation of the reagent formulations through the formal validation according to the ICH Q2(R1) and the bioanalytical‑method‑validation guidelines of the FDA and the EMA, to the routine batch‑release testing, the accelerated and the real‑time stability monitoring, and the investigation of the customer‑reported performance deviations. For a producer exporting a cardiac‑troponin‑I ELISA to the European Union, a food‑testing laboratory certifying a peanut‑allergen screening kit, or a vaccine manufacturer releasing an anti‑drug‑antibody bridging ELISA, this service provides the legally robust, defensible data that underpin the CE marking, the 510(k) clearance, the product registration and the confidence of the end user in every test result.

Product Samples We Regularly Subject to ELISA Kit Testing

The microplate readers, the automated liquid‑handling workstations, the temperature‑controlled incubators, the stability‑storage chambers and the statistical‑analysis software in our facility accommodate a vast variety of ELISA kit formats and their individual components. The following categories represent the most frequently tested items:

Clinical diagnostic ELISA kits – the sandwich, the competitive and the indirect ELISA formats for the quantification of the cardiac markers, the tumour biomarkers, the hormones, the cytokines, the infectious‑disease serology markers and the therapeutic‑drug‑monitoring analytes
Biopharmaceutical and the immunogenicity monitoring kits – the bridging‑format and the direct‑format anti‑drug‑antibody ELISA kits, the neutralizing‑antibody assay kits, and the pharmacokinetic ELISA kits for the measurement of the therapeutic monoclonal antibodies and the Fc‑fusion proteins
Food‑allergen and the food‑safety ELISA kits – the sandwich ELISA kits for the detection and the quantification of the peanut, the tree‑nut, the milk, the egg, the soy, the wheat, the crustacean and the mustard allergens, and the ELISA kits for the mycotoxins, the antibiotics and the veterinary‑drug residues in the food and the feed matrices
Environmental and the water‑quality ELISA kits – the kits for the detection of the pesticides, the herbicides, the endocrine‑disrupting compounds, the algal toxins and the industrial contaminants in the surface water, the groundwater and the soil extracts
Veterinary and the animal‑health ELISA kits – the serological kits for the surveillance of the foot‑and‑mouth disease, the avian influenza, the bovine tuberculosis and the other notifiable animal diseases, and the kits for the detection of the antibiotic residues in the milk and the meat
Individual kit components and the critical raw materials – the pre‑coated microtitre plates, the lyophilised standards and the controls, the enzyme‑conjugated detection antibodies, the chromogenic substrates and the wash‑buffer concentrates, submitted for the incoming‑quality‑control and the supplier‑qualification testing

Assay Validation and the Performance Characterisation – ELISA Kit Testing According to ICH Q2(R1), USP ⟨1032⟩ and the Bioanalytical Method Validation Guidelines

Determination of the calibration‑curve performance, the limit of detection and the limit of quantification according to the internal validated protocol and the principles of ICH Q2(R1) (Validation of Analytical Procedures) and the FDA Guidance for Industry on Bioanalytical Method Validation: the calibration standards that are supplied with the kit, or the independently prepared reference standards, are assayed in the replicates across the multiple analytical runs, and the observed mean response is fitted to a four‑parameter or a five‑parameter logistic regression model. The back‑calculated concentrations of the calibration standards, the correlation coefficient and the precision profile of the standard curve are reported. The limit of detection – the lowest concentration that can be reliably distinguished from the blank – and the lower and the upper limits of quantification are determined, providing the fundamental performance parameters that are declared in the kit‑insert and that are verified by the independent testing. This ELISA kit testing service ensures that the calibration model and the working range claimed by the manufacturer are accurate and reproducible.
Assessment of the intra‑assay and the inter‑assay precision and the accuracy by the replicate‑analysis of the quality‑control samples at the multiple concentration levels: the kit‑supplied or the independently prepared quality‑control samples that span the low, the medium and the high regions of the calibration range are assayed in a minimum of six replicates within a single run and across at least six independent runs performed on the different days, by the different operators and with the different reagent lots. The coefficient of variation for the intra‑assay and the inter‑assay precision, and the percentage relative error for the accuracy, are calculated and compared with the acceptance criteria – typically ≤ 15 % for the precision and within ± 15 % for the accuracy at all levels except the lower limit of quantification, where ≤ 20 % may be accepted. The data provide the evidence that the ELISA kit generates the consistent, reliable results across the expected range of the operational variability.
Dilution‑linearity and the parallelism testing for the demonstration of the sample‑matrix compatibility: the native or the spiked sample matrices that are representative of the intended use – the human serum, the plasma, the urine, the cell‑culture supernatant or the food‑extract – are serially diluted and assayed, and the observed concentration is plotted against the dilution factor. The linearity of the response across the dilution range and the parallelism between the dilution‑corrected sample curve and the standard curve are evaluated, confirming that the assay measures the analyte consistently regardless of the sample dilution and that the matrix components do not interfere with the antigen‑antibody binding.
Determination of the specificity and the cross‑reactivity against the structurally related compounds and the common interferents: a panel of the potentially cross‑reacting molecules – the metabolites, the co‑administered drugs, the endogenous analogues and the matrix‑derived heterophilic antibodies – is assayed at the physiologically relevant concentrations, and the apparent analyte concentration that is generated by each cross‑reactant is reported as a percentage of the nominal concentration, providing the critical data for the risk‑assessment of the false‑positive or the inflated results in the clinical and the food‑safety applications.
Robustness and the ruggedness testing by the deliberate variation of the assay parameters: the incubation time, the incubation temperature, the wash‑cycle number, the substrate‑incubation time and the reagent‑lot are varied within the ranges that are likely to occur in the routine laboratory practice, and the effect on the calibration‑curve parameters, the quality‑control recovery and the selected sample results is quantified, identifying the steps that are the most critical for the assay performance and that must be the focus of the user‑training and the troubleshooting guidance.

Batch Release, Stability and the Comparability Testing – ELISA Kit Testing Service for the Quality‑Control and the Lifecycle Management

Batch‑release testing of the finished ELISA kit according to the internal validated protocol and the principles of the ISO 13485 (Medical devices – Quality management systems) and the FDA Quality System Regulation: a statistically representative sample of the finished kits from each production batch is tested against the pre‑defined release specifications, which typically include the calibration‑curve performance, the recovery of the kit‑supplied quality‑controls, the background optical‑density of the blank wells, and the appearance and the integrity of the physical components. The batch is released only if all the parameters meet the specification, and the certificate of analysis that summarises the release‑test data is issued, providing the objective evidence that the kit that reaches the customer is equivalent to the kit that was validated. This ELISA kit testing service can be performed as a fully independent, third‑party batch‑release function, removing the potential conflict of interest and strengthening the regulatory compliance.
Real‑time and the accelerated stability testing of the ELISA kit according to the principles of the ICH Q1A (Stability Testing of New Drug Substances and Products) and the CLSI EP25 (Evaluation of Stability of In Vitro Diagnostic Reagents): the complete kits and the individual, unpackaged components are stored under the real‑time conditions (e.g., 2 °C to 8 °C for the refrigerated kits) for the duration of the claimed shelf‑life, and at the accelerated conditions (e.g., 25 °C, 37 °C or 45 °C) for the shorter periods. At the pre‑defined time‑points, the kits are removed and tested, and the trend of the calibration‑curve slope, the quality‑control recovery, the background signal and the colour‑development kinetics is analysed. The real‑time data establish the expiration‑dating, and the accelerated‑stability data support the transport‑excursion and the tropical‑storage label claims.
Comparability and the bridging studies for the manufacturing‑process changes, the reagent‑resourcing and the kit‑reformulation: when the manufacturer changes a critical raw material, modifies the coating or the conjugation protocol, or transfers the production to a new facility, the side‑by‑side testing of the pre‑change and the post‑change kit lots is performed on a panel of the well‑characterised samples, and the statistical equivalence of the results is demonstrated by the Bland‑Altman analysis, the Deming regression or the concordance‑correlation coefficient, supporting the regulatory notification and the customer‑communication process.
Transport‑simulation and the shipping‑validation testing: the packaged kits are subjected to the controlled drop, the vibration and the temperature‑cycling regimes that simulate the real‑world distribution chain, and the post‑simulation performance is compared with the un‑stressed control, verifying that the kit can withstand the rigours of the global shipping without the loss of the accuracy or the precision.

Food‑Safety, Environmental and the Specialised Application Testing – ELISA Kit Testing Service for the Regulatory and the Accreditation Compliance

Validation of the food‑allergen and the mycotoxin ELISA kits according to the AOAC International Performance Tested Methods program and the European Union Reference Laboratory guidelines: the kit is tested on the incurred and the spiked food matrices that are representative of the intended scope – the bakery products, the chocolate, the infant formula, the wine and the edible oils – and the probability of the detection at the regulatory limit, the intra‑ and the inter‑laboratory reproducibility, and the cross‑reactivity against the other allergens or the mycotoxins are determined, providing the data package that the manufacturer submits to the AOAC or the other certification bodies for the independent method approval. This ELISA kit testing service enables the kit producer to obtain the Performance Tested Methods certification, which is the globally recognised mark of the reliable food‑safety testing.
Environmental‑monitoring ELISA kit validation for the water‑quality and the soil‑contaminant analysis according to the EPA SW‑846 methods and the ISO 17353 (Water quality – Determination of selected organotin compounds – Gas chromatographic method, adapted for the immunoassay validation): the kit is challenged with the real environmental samples that contain the known concentrations of the target analyte, and the correlation with the reference chromatographic or the mass‑spectrometric method is established, demonstrating the suitability of the ELISA kit as a cost‑effective, high‑throughput screening tool for the environmental surveillance programmes.
Kit‑component and the reagent‑raw‑material testing: the individual reagents – the coated plates, the detection antibodies and the enzyme conjugates – are tested for the activity, the stability and the absence of the microbial contamination, providing the incoming‑quality‑control data that the kit manufacturer uses to qualify the suppliers and to monitor the consistency of the critical raw materials.
Troubleshooting and the customer‑complaint investigation: for the kits that have exhibited an unexpected performance issue in the field, the retained samples from the complaint lot are re‑analysed, and the root‑cause investigation – whether the under‑performing reagent, the damaged packaging or the end‑user procedural error – is conducted, providing the objective, independent report that the manufacturer can use to resolve the dispute with the customer or to file the regulatory field‑safety notice.

Report Acceptance and Global Regulatory Compliance

All measurements performed within our ELISA kit testing service are executed under the fully accredited scope of our ISO/IEC 17025 quality management system. Each test report that carries the ILAC mark is therefore automatically recognised by regulatory authorities, notified bodies, customs offices and supply‑chain partners in all major economies. For diagnostic manufacturers, pharmaceutical developers, food‑safety testing laboratories and environmental‑monitoring agencies anywhere in the world, the report constitutes legally robust, internationally accepted evidence that the sensitivity, the specificity, the precision, the accuracy, the robustness, the batch‑to‑batch consistency and the stability of the ELISA kit have been determined in accordance with the applicable ICH, USP, FDA, EMA, AOAC, CLSI and customer‑specified methods. The documentation can be directly used to support the CE marking under the In Vitro Diagnostic Medical Devices Regulation, the FDA 510(k) clearance, the product registration with the national competent authorities, the issue of inspection certificates according to EN 10204 or equivalent national standards, and the resolution of commercial and technical disputes concerning the performance and the reliability of any enzyme‑linked immunosorbent assay product.